StockNews.AI
TVGN
StockNews.AI
21 days

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

1. TVGN 116's rNPV exceeds $325 million for U.S. market. 2. 5-year revenue forecast for TVGN 116 estimated at $6.5 billion. 3. Tevogen claims unique drug development model for sustainability. 4. Progress on TVGN 489 supports rapid milestone achievements. 5. Forward-looking statements address various operational risks.

Earnings
-3.08%Current Return
VS
+0.36%S&P 500
$0.900209/09 03:21 PM EDTEvent Start
$0.872509/10 09:19 PM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Bullish?

The projected revenue and rNPV suggest strong growth potential, similar to successful biotech stocks. Historical instances show positive market responses to high rNPV figures.

How important is it?

The estimates for TVGN 116 directly impact investor perception and stock valuation. As this product progresses, it could drastically alter market outlook.

Why Long Term?

The forecast indicates a significant revenue stream over five years, allowing for sustained market confidence, akin to patterns seen in similar biotech advancements.

Related Companies

VRTXGILDAMGN
Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections. The TVGN 116 cumulative 5-year top-line revenue forecast is estimated to be ~$6.5 billion. The forecast reflects the Company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come. The current rNPV projection for this internally developed asset exceeds ~$325 million. This is based on our current understanding of the unmet medical needs and the competitive landscape. The risk adjustment resets at each milestone in the product development lifecycle, and Tevogen’s progress with its first clinical-stage product, TVGN 489, highlights the rapid pace at which such milestones can be achieved. Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 Communications@Tevogen.com

Related News